The Patent Finder

Yangtze River Pharmaceutical Group Co., Ltd.

18 patents currently held · Updated Nov 20, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

1
Ending by 2030
Jul 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jul 28, 2027
    The maintenance fee for PI3K inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof (US 10,544,137) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 4 of the patents on this record were granted since Aug 22, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,820,692Tetrahydro Isoquinoline Derivatives, Preparation Methods and Medicinal Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,100,047Piperidine derivatives as orexin receptor antagonist
In force
 · USPTO record
In forceUSPTO record
US 9,884,870Polymorphic substance of yonkenafil hydrochloride, preparation method therefor, and composition and use thereof
In force
 · USPTO record
In forceUSPTO record
US 10,227,3242-Morpholin-4,6-Disubstituted Pyrimidine Derivative, and Preparation Method and Pharmaceutical Use Thereof
In force
 · High confidence
In forceHigh confidence
US 10,668,066Crystal form of orexin receptor antagonist compound, and preparation method and application thereof
In force
 · USPTO record
In forceUSPTO record
US 10,874,674Crystal form of orexin receptor antagonist compound, and preparation method and application thereof
In force
 · USPTO record
In forceUSPTO record
US 10,898,486Crystal form of orexin receptor antagonist compound, and preparation method and application thereof
In force
 · USPTO record
In forceUSPTO record
US 10,912,775Crystal form of orexin receptor antagonist compound, and preparation method and application thereof
In force
 · USPTO record
In forceUSPTO record
US 10,815,197N-sulfonyl benzamides as voltage-gated sodium channel inhibitors
In force
 · USPTO record
In forceUSPTO record
US 10,544,137PI3K inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof
In force
 · USPTO record
In forceUSPTO record
10 of 18 patents shown.
Pro members see all 18.
Pro members: see all 18 patents
Also on record, not counted in the 18: 13 lapsed for an unpaid fee · 4 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 10 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited